NERV Stock Price, Minerva Neurosciences Quote, Chart

Market Summary

USD2.54-0.03

Delayed

-1.17%

NERV Stock Price

View Fullscreen

NERV RSI Chart

NERV Valuation

Market Cap

17.8M

Price/Earnings (Trailing)

-0.56

EV/EBITDA

0.57

Price/Free Cashflow

-0.86

MarketCap/EBT

-0.52

NERV Price/Sales (Trailing)

NERV Profitability

Return on Equity

86.38%

Return on Assets

-62.57%

Free Cashflow Yield

-116.92%

NERV Fundamentals

NERV Earnings

Earnings (TTM)

-31.6M

Earnings Growth (Yr)

-22.93%

Earnings Growth (Qtr)

5.03%

Breaking Down NERV Revenue

Last 7 days

6.3%

Last 30 days

2.8%

Last 90 days

-69.7%

Trailing 12 Months

-62.3%

How does NERV drawdown profile look like?

NERV Financial Health

Current Ratio

12.58

NERV Investor Care

Shares Dilution (1Y)

25.59%

Diluted EPS (TTM)

-4.46

Tracking the Latest Insider Buys and Sells of Minerva Neurosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2023	luthringer remy	sold	-13,690	3.76	-3,641	ceo
May 01, 2023	luthringer remy	sold	-91,449	3.85	-23,753	ceo
May 01, 2023	race geoff	sold	-85,015	3.85	-22,082	president
May 01, 2023	ahlholm frederick w	sold	-16,038	4.48	-3,580	svp, cfo and secretary
Apr 28, 2023	luthringer remy	acquired	-	-	88,077	ceo
Apr 28, 2023	race geoff	acquired	-	-	46,987	president
Apr 28, 2023	ahlholm frederick w	acquired	-	-	19,843	svp, cfo and secretary
Dec 01, 2021	kupfer david	sold	-48,958	0.88	-55,635	-
Dec 16, 2020	race geoff	sold	-16,341	2.64	-6,190	evp, cfo & cbo
Dec 16, 2020	ahlholm frederick w	sold	-4,870	2.64	-1,845	svp, chief accounting officer

Which funds bought or sold NERV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-58,973	42,619	-%
May 15, 2024	MORGAN STANLEY	added	70.97	-10,931	27,728	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-2.34	-465	322	-%
May 15, 2024	Anchor Investment Management, LLC	unchanged	-	-43.00	31.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	201	2,222	10,586	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-357	258	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	54.14	-140,479	257,082	0.02%
May 15, 2024	Royal Bank of Canada	added	11.13	-2,000	1,000	-%
May 14, 2024	NORTHERN TRUST CORP	reduced	-7.6	-94,102	59,563	-%
May 14, 2024	FEDERATED HERMES, INC.	unchanged	-	-4,824,050	3,486,290	0.01%

Are Funds Buying or Selling NERV?

Are funds buying NERV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NERV

No. of Funds

Unveiling Minerva Neurosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 18, 2024	federated hermes, inc.	19.32%	1,351,275	SC 13G/A
Jul 07, 2023	boehringer ag	20.79%	1,500,225	SC 13D
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	3.63%	193,938	SC 13G/A
Feb 01, 2023	federated hermes, inc.	22.50%	1,201,275	SC 13G/A
Aug 23, 2022	point72 asset management, l.p.	8.8%	470,000	SC 13G
Feb 14, 2022	federated hermes, inc.	22.50%	9,610,200	SC 13G/A
Feb 11, 2022	luthringer remy	2.5%	1,059,761	SC 13G/A
Nov 24, 2021	assenagon asset management s.a.	14.23%	6,081,312	SC 13G

Recent SEC filings of Minerva Neurosciences Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	10-Q	Quarterly Report
Apr 22, 2024	10-K/A	Annual Report
Apr 12, 2024	8-K	Current Report
Feb 27, 2024	8-K	Current Report
Feb 26, 2024	10-K/A	Annual Report
Feb 22, 2024	10-K	Annual Report
Feb 09, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Minerva Neurosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Minerva Neurosciences Inc News

Latest updates

Minerva Neurosciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.2%	51.00	57.00	63.00	67.00	52.00	55.00	60.00	65.00	71.00	77.00	98.00	105	112	58.00	65.00	66.00	69.00	77.00	111	120	130
Current Assets	-15.2%	36.00	42.00	48.00	52.00	37.00	40.00	45.00	50.00	56.00	62.00	67.00	75.00	82.00	27.00	35.00	36.00	38.00	47.00	61.00	71.00	80.00
Cash Equivalents	-14.7%	35.00	41.00	47.00	52.00	36.00	36.00	40.00	50.00	55.00	61.00	66.00	74.00	80.00	25.00	33.00	32.00	30.00	21.00	38.00	28.00	31.00
Net PPE	-12.5%	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
Liabilities	2.0%	87.00	85.00	83.00	80.00	78.00	75.00	74.00	73.00	71.00	69.00	69.00	69.00	66.00	5.00	7.00	9.00	50.00	50.00	55.00	53.00	52.00
Current Liabilities	-15.3%	3.00	3.00	3.00	2.00	3.00	1.00	2.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	5.00	7.00	7.00	7.00	10.00	8.00	7.00
Shareholder's Equity	-28.6%	-36.59	-28.46	-	-	-26.62	-20.02	-	-	-	8.00	28.00	36.00	45.00	53.00	58.00	57.00	19.00	28.00	56.00	67.00	77.00
Retained Earnings	-2.2%	-405	-396	-387	-379	-373	-366	-360	-353	-344	-334	-313	-304	-344	-284	-277	-304	-298	-286	-256	-242	-230
Additional Paid-In Capital	0.1%	369	368	368	367	347	347	346	345	344	343	341	340	339	337	335	326	318	315	312	310	308
Shares Outstanding	0%	7.00	7.00	7.00	7.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	37.00	-	-	-	17.00	-	-	-	96.00	-	-	-	141	-	-	-	211	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1.8%	-6,100	-5,991	-4,806	-3,871	-115	-4,110	-9,533	-5,192	-5,808	-4,833	-8,626	-5,924	-5,217	-7,158	-9,871	-7,589	-9,202	-14,180	-9,521	-10,129	-9,600
Share Based Compensation	-28.2%	439	611	372	609	376	948	1,037	1,072	1,053	1,204	1,115	1,384	1,516	1,965	2,056	3,485	2,198	2,170	2,221	2,320	2,462
Cashflow From Investing	-	-	-	-	-	-	-16.33	-	-	-	-	-	-	-	-	3,000	4,500	17,028	-2,312	19,582	7,366	-10,551
Cashflow From Financing	-	-	-	-86.69	19,690	-	-	-	-	-	-	-	-	60,000	-	7,135	5,305	798	-1*	-	-	525

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NERV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Expenses
Research and development	$ 4,167,287	$ 2,653,553
General and administrative	2,514,676	2,694,965
Total expenses	6,681,963	5,348,518
Loss from operations	(6,681,963)	(5,348,518)
Foreign exchange gains (losses)	5,493	(8,686)
Investment income	357,908	364,218
Non-cash interest expense for the sale of future royalties	(2,250,243)	(1,977,426)
Net loss	$ (8,568,805)	$ (6,970,412)
Net loss per share, basic	$ (1.13)	$ (1.31)
Net loss per share, diluted	$ (1.13)	$ (1.31)
Weighted average shares outstanding, basic	7,568,981	5,340,193
Weighted average shares outstanding, diluted	7,568,981	5,340,193

NERV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 34,818,304	$ 40,912,575
Restricted cash	100,000	100,000
Prepaid expenses and other current assets	702,546	989,865
Total current assets	35,620,850	42,002,440
Equipment, net	9,524	10,884
Capitalized software, net	10,642	17,027
Goodwill	14,869,399	14,869,399
Total assets	50,510,415	56,899,750
Current liabilities
Accounts payable	1,435,568	1,805,320
Accrued expenses and other current liabilities	1,395,227	1,535,097
Total current liabilities	2,830,795	3,340,417
Liability related to the sale of future royalties	84,267,066	82,016,823
Total liabilities	87,097,861	85,357,240
Commitments and contingencies (Note 8)
Stockholders' deficit
Preferred stock; $0.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2024 and December 31, 2023
Common stock; $0.0001 par value; 125,000,000 shares authorized; 6,993,406 shares issued and outstanding as of March 31, 2024 and December 31, 2023	699	699
Additional paid-in capital	368,796,088	368,357,239
Accumulated deficit	(405,384,233)	(396,815,428)
Total stockholders' deficit	(36,587,446)	(28,457,490)
Total liabilities and stockholders' deficit	$ 50,510,415	$ 56,899,750

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Remy Luthringer Ph.D.
WEBSITE	minervaneurosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Minerva Neurosciences Inc Frequently Asked Questions

What is the ticker symbol for Minerva Neurosciences Inc? What does NERV stand for in stocks?

NERV is the stock ticker symbol of Minerva Neurosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Minerva Neurosciences Inc (NERV)?

As of Fri May 17 2024, market cap of Minerva Neurosciences Inc is 17.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NERV stock?

You can check NERV's fair value in chart for subscribers.

What is the fair value of NERV stock?

You can check NERV's fair value in chart for subscribers. The fair value of Minerva Neurosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Minerva Neurosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NERV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Minerva Neurosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NERV is over valued or under valued. Whether Minerva Neurosciences Inc is cheap or expensive depends on the assumptions which impact Minerva Neurosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NERV.